HRTS – Tema Cardiovascular and Metabolic ETF
Tema Cardiovascular and Metabolic ETF (HRTS) is a Health ETF, issued by Tema Global Limited, $57.6M in assets, 0.75% expense ratio.
Returns as of Oct 23, 2026: 1 week +1.5%, 1 year +25.9%.
Focuses on companies deriving 50%+ revenue from GLP-1 and cardiovascular/metabolic disease treatments. Typically includes 15-100 companies in the portfolio.
Top holdings
- LLY – Eli Lilly and Company, 10.3%
- RHHBY – Roche Holding Ltd ADR, 5.2%
- UNH – UnitedHealth Group Incorporated, 4.6%
- JNJ – Johnson & Johnson, 4.4%
- AZN – AstraZeneca PLC, 4.3%
- TMO – Thermo Fisher Scientific Inc, 4.2%
- MRK – Merck & Company Inc, 4.1%
- ABT – Abbott Laboratories, 3.6%
- 0QIU – Novo Nordisk A/S Class B, 3.6%
- NOVN – Novartis AG, 3.2%
- GILD – Gilead Sciences Inc, 3.1%
- BSX – Boston Scientific Corp, 3.0%
- MDT – Medtronic PLC, 3.0%
- ABBV – AbbVie Inc, 2.8%
- DHR – Danaher Corporation, 2.8%
- VRTX – Vertex Pharmaceuticals Inc, 2.7%
- BBIO – BridgeBio Pharma Inc, 2.3%
- RVMD – Revolution Medicines Inc, 2.3%
- AMGN – Amgen Inc, 2.1%
- REGN – Regeneron Pharmaceuticals Inc, 2.0%
- BMY – Bristol-Myers Squibb Company, 1.9%
- MCK – McKesson Corporation, 1.9%
- 4519 – Chugai Pharmaceutical Co. Ltd., 1.7%
- ISRG – Intuitive Surgical Inc, 1.6%
- EW – Edwards Lifesciences Corp, 1.6%